Home / Radiology & Imaging AI / MEDO ARIA

MEDO ARIA

by Medo.ai · Based in Canada → — AI for accessible ultrasound imaging and diagnostics.

Orthopedics Pediatrics Radiology

Website

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

N/a

Regulatory Status Disclosed

Overview

Medo.ai is a developer of artificial intelligence technology focused on making ultrasound imaging faster, simpler, and more accessible. The company’s technology integrates AI and cloud computing with ultrasound devices to enable even novice users to detect common and critical conditions. Their vision is to bring medical imaging to anyone, whenever and wherever it’s needed, by radically lowering the expertise required for diagnosis through automated image acquisition and interpretation.

Medo.ai’s flagship product, MEDO ARIA (Automated Real-time Intelligent Assistant), received U.S. FDA 510(k) clearance in June 2020 for detecting developmental dysplasia of the hip (DDH) on ultrasound exams in infants. The company has developed multiple FDA-cleared AI algorithms, with more in development, and has strong partnerships with health systems globally. Medo.ai was acquired by Exo (Exo Imaging), a health information and medical devices company, in July 2022, with its proprietary Sweep AI™ technology being integrated into Exo’s ultrasound platform.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

AI-powered ultrasound technology
Automated image acquisition
Automated image interpretation
Detection of common and critical conditions
Specifically detects hip dysplasia in infants
Lowers expertise required for ultrasound diagnosis
Integrates with ultrasound devices
Cloud computing capabilities
Proprietary Sweep AIu2122 technology

Use Cases

Point-of-care ultrasound diagnostics
Early disease detection
Improving diagnostic accuracy for non-experts
Screening for Developmental Dysplasia of Hip (DDH)
Expanding access to medical imaging for caregivers

What Physicians Need to Know

DICOM Support & Standards

MEDO ARIA processes imported DICOM ultrasound images, adhering to the Digital Imaging and Communications in Medicine (DICOM) standard for image data interchange.

PACS Integration Method

As a cloud-based standalone software, MEDO ARIA is designed to securely connect with common Picture Archiving and Communication Systems (PACS) and Electronic Medical Records (EMR) systems. Integration typically leverages existing DICOM infrastructure, potentially following a 'DICOM Node (Pull-Process-Push)' pattern.

Reading Room Workflow Impact

MEDO ARIA aims to improve workflow efficiency by automating image analysis tasks, such as selecting optimal images, calculating standard measurements, and assisting in classification and report generation. For developmental dysplasia of the hip (DDH), it helps automate image analysis and reporting, reducing indeterminate cases and improving diagnostic accuracy. For thyroid, it simplifies the scanning workflow by automatically reviewing video sweeps and characterizing nodules using TI-RADS.

AI Model Architecture (deep learning approach)

The tool utilizes machine learning techniques, specifically a Convolutional Neural Network (CNN) for its DDH application, trained on a large dataset of labeled hip ultrasound images. It performs image-based assessment, including manual and semi-automatic landmark placement, alpha angle and coverage measurements, and hip Graf classification.

FDA Clearance Pathway (510k/De Novo)

MEDO ARIA received 510(k) clearance (K200356) from the U.S. Food and Drug Administration (FDA) on June 11, 2020, for the diagnosis of developmental dysplasia of the hip (DDH) in infants. The company also received 510(k) clearance for its Medo-Thyroid AI software in May 2021.

Supported Modalities (CT/MRI/X-ray/US)

MEDO ARIA is specifically designed for **Ultrasound (US)** images, focusing on infant hip ultrasound for DDH and thyroid ultrasound for nodule assessment.

Sensitivity & Specificity Data

For the DDH application, studies evaluating the MEDO-Hip AI app reported sensitivity ranging from 86.54% to 100% and specificity from 62.5% to 100% for ultrasound images. The AI and 3D-based technology has been shown to be as accurate as expert radiologists in diagnosing hip dysplasia.

Physician Tip

Leverage MEDO ARIA to streamline routine ultrasound image analysis for infant hip dysplasia and thyroid nodule assessment, potentially reducing reading times and improving consistency. The AI's ability to automatically select optimal images and perform measurements can be particularly beneficial for less experienced users or in high-volume settings. Always integrate AI findings with clinical context and your expert judgment, as the tool is intended to aid, not replace, medical professionals.

MEDO ARIA is a cloud-based solution designed for secure integration with existing PACS and EMR systems. This allows for seamless import of DICOM ultrasound images and potential export of AI-generated reports or structured findings back into the clinical workflow. Facilities should ensure their IT infrastructure supports cloud-based AI solutions and standard DICOM communication protocols for optimal integration and data flow.

At a glance

Pricing N/a

Deployment Cloud Based

Visit site

Details

Category	Radiology & Imaging AI
Pricing	N/a — N/A
Deployment	Cloud-based
Compliance
BAA Available	Unknown AI-estimated
HIPAA Compliant	Unknown AI-estimated
FDA Status	1 AI-estimated MEDO ARIA (Automated Real-time Intelligent Assistant) received U.S. FDA 510(k) clearance (K200356) on June 11, 2020, for detecting hip dysplasia on ultrasound exams in infants. Medo.ai has two FDA-cleared AI algorithms.
Integrations
EHR	Not specified
Specialties	Orthopedics, Pediatrics, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate MEDO ARIA

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

Press & Coverage

GlobeNewswire

MEDO.ai receives FDA approval to automatically detect hip dysplasia, preventing the leading cause of early hip osteoarthritis and hip replacement surgery.

MEDO.ai received FDA 510(k) clearance for its ARIA (Automated Real-time Intelligent Assistant) software, the world's first AI tool to detect hip dysplasia on ultrasound exams in infants. This innovation aims to enable quick and accurate diagnosis during routine infant check-ups, potentially leading to universal screening and preventing early hip osteoarthritis.

2020-06

AuntMinnie

Medo.ai gets FDA nod for hip dysplasia AI software

Medo.ai's ARIA, an AI software application, has received FDA 510(k) clearance for detecting hip dysplasia in infants using ultrasound. The software automatically reviews images, calculates measurements, and assists clinicians in classifying and diagnosing hips, with accuracy comparable to expert radiologists.

2020-06

accessdata.fda.gov

510(k) summary: MEDO ARIA [Premarket notification submission K200356]

The FDA 510(k) summary details the clearance of MEDO ARIA, a cloud-based standalone software as a medical device (SaMD) designed to view and quantify ultrasound image data using machine learning to aid in the diagnosis of developmental dysplasia of the hip (DDH) in infants aged 0 to 12 months.

2020-06

Imaging Technology News

Medo AI and Medical Imaging Consultants Announce Partnership to Simplify Diagnostic Ultrasound Imaging

Medo AI partnered with Medical Imaging Consultants (MIC) to revolutionize diagnostic imaging, focusing on simplifying ultrasound exams, particularly for thyroid assessments. This collaboration aims to improve patient experience and guide Medo's strategic roadmap for product development.

2021-12

Business Wire

Exou00ae Acquires Medo AI to Make Medical Imaging as Easy as Snapping a Smartphone Photo

Exo, a health information and medical devices company, acquired Medo AI to integrate its proprietary Sweep AIu2122 technology into Exo's ultrasound platform. This acquisition aims to make ultrasound imaging faster, simpler, and more accessible to a wider range of caregivers by reducing the expertise required for image capture and interpretation.

2022-07

HIT Consultant

Exo Acquires Medo to Make Ultrasounds Simple and Accessible

Exo's acquisition of Medo AI is set to simplify ultrasound imaging by integrating Medo's FDA-cleared AI platform into Exo's workflow. This move is expected to make point-of-care ultrasound (POCUS) more accessible to clinicians without extensive ultrasound training, improving patient care through faster and more accurate diagnoses for conditions like hip dysplasia and thyroid nodules.

2022-07

PMC (PubMed Central)

A scoping review of reporting gaps in FDA-approved AI medical devices - PMC

This review highlights MEDO ARIA software as one of the few FDA-approved AI medical devices specifically designed for pediatric patients, assisting in the image-based assessment of developmental hip dysplasia (DDH) in infants aged 0 to 12 months.

2024-04

PMC (PubMed Central)

Remote diagnostic imaging using artificial intelligence for diagnosing hip dysplasia in infants: Results from a mixed-methods feasibility pilot study - PMC

A pilot study demonstrated the feasibility of using the MEDO-Hip app with AI technology for remote diagnostic imaging of hip dysplasia in infants in primary care settings. The AI assessed scans in real-time, providing results and reports, with high rates of normal hips and identified DDH cases.

2023-04

Videos

Product demos, reviews, and walkthroughs for MEDO ARIA.

MeDo AI Review - 2026 | I Turned a Simple Idea Into a Live App Using This AI

Best AI App Builder? MeDo Builds Frontend, Backend & Payments Automatically - VIBE CODING KING?

Introducing MeDo

View all on YouTube

Frequently Asked Questions

How does MEDO ARIA integrate into current clinical workflows for infant hip ultrasound screening?

MEDO ARIA is a cloud-based software that processes imported DICOM ultrasound images of infant hips. It assists clinicians by automatically reviewing images, selecting optimal views, calculating measurements, and generating reports to aid in the diagnosis of developmental dysplasia of the hip (DDH), thereby streamlining the workflow for radiologists and other trained medical professionals.

What regulatory clearances does MEDO ARIA hold, and how does it address patient data privacy and security?

MEDO ARIA has received U.S. Food and Drug Administration (FDA) 510(k) clearance as a Class II medical device. Its safety and performance have been verified according to software specifications and applicable standards like IEC 62304, ensuring compliance with medical device software lifecycle processes.

What are the known limitations or potential challenges associated with using MEDO ARIA in a clinical setting?

MEDO ARIA is specifically designed for neonates and infants aged 0 to 12 months for the diagnosis of developmental dysplasia of the hip (DDH) using ultrasound. While it aims to simplify image interpretation and can be used by lightly trained primary care staff, its application is currently focused on this specific condition and age group.

How accurate is MEDO ARIA in diagnosing hip dysplasia compared to expert radiologists?

Medo.ai has stated that its AI and 3D-based technology has been shown to be as accurate as expert radiologists in diagnosing hip dysplasia. Studies have also indicated that AI-supported portable ultrasound, like MEDO-Hip, can enable lightly trained primary care staff to perform hip dysplasia screening with detection rates similar to formal ultrasound screening performed by sonographers and interpreted by radiologists.

What are the primary alternatives to MEDO ARIA for infant hip dysplasia screening and diagnosis?

Alternatives to MEDO ARIA include traditional ultrasound screening performed and interpreted by expert sonographers and radiologists. While the search results mention general AI alternatives for clinical solutions, for infant hip dysplasia specifically, the primary alternative remains expert human interpretation of ultrasound images.

What level of training is required for medical professionals to effectively utilize MEDO ARIA?

MEDO ARIA is designed to aid trained medical professionals, and its technology aims to radically lower the expertise required for diagnosis. Studies suggest that even lightly trained primary care clinic staff, such as nurses or family physicians, can effectively perform DDH ultrasound using handheld ultrasound with AI decision support like MEDO-Hip, after training via video, PowerPoint, and brief in-person sessions.

What is the typical pricing structure for MEDO ARIA, and is it generally covered by insurance?

Specific pricing details for MEDO ARIA are not publicly available in the provided search results. However, as a medical device, its cost would typically involve licensing fees or a subscription model, and coverage by insurance would depend on individual payer policies and the specific CPT codes used for hip ultrasound and AI-assisted interpretation.

Related Tools

Surgical Reality Viewer

Surgical Reality

Oncology AI

Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.

Oxipit ChestLink

Oxipit (part of Sectra group)

Clinical Decision Support & Reference

Oxipit ChestLink is the world's first CE Class IIb-certified autonomous AI application for healthy chest X-ray reporting, capable of identifying normal studies with 99.9% sensitivity. It automates the reporting of normal chest X-rays, reducing radiologist workload and improving efficiency.

Cercare Medical Oncology Virtual Expert

Cercare Medical

Neurology AI

Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.

CARPL.ai

Developer Tools & APIs

CARPL.ai is a vendor-neutral Artificial Intelligence (AI) platform that allows radiologists to access, assess, and integrate radiology AI solutions in their clinical practice. It provides a single user interface, a single data channel, and a single procurement channel for the testing, deployment, and monitoring of AI solutions in clinical radiology workflows.

CoLumbo C-Spine

Smart Soft Healthcare AD

Clinical Decision Support & Reference

CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.

SubtleHD-CT

Subtle Medical, Inc.

Radiology & Imaging AI

Subtle Medical's SubtleHD-CT is an AI software designed to enhance the quality and resolution of CT scans, reducing noise and improving image clarity. [7]

See all Radiology & Imaging AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18